Palmar FibromatosisNCT07443371
Effect of Transfer Energy Capacitive and Resistive Therapy on Palmar Fibromatosis
A study testing Transfer Energy Capacitive and Resistive (TECAR) therapy and Traditional therapy in people with Palmar Fibromatosis, run by Cairo University at 1 site in Egypt.
Trial summary
The objective of the present study is to explore the effect of Transfer Energy Capacitive and Resistive Therapy (TECAR) therapy on pain, range of motion (ROM) and hand function in dupuytren's contracture patients (palmar fibromatosis). Read more about this study
- Who is it for?
- Ages 40 to 70 years
- Conditions the study is for
- Palmar Fibromatosis
- What is being tested?
- Transfer Energy Capacitive and Resistive (TECAR) therapy and Traditional therapy
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 36 participants
- Where
- 1 siteEgypt
- Study dates
- 2 Mar 2026to 30 May 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Ages of patients will be ranged from 40 to 70 years.
- Presence of palpable cords and/or digital contracture ≥ 20° at the metacarpophalengeal joint or Proximal interphalengeal joint joints .
- Clinical diagnosis confirmed by a hand surgeon or relevant specialist.
- All patients will enter the study having their informed consent
Who cannot join
- Patient with severe contracture >30° or multiple digit involvement requiring surger.
- History of surgical release (fasciotomy, fasciectomy) or collagenase injection in the affected hand.
- Presence of infection, ulceration, or skin lesions on the treatment area.
- Presence of pacemakers, metal implants, or other electronic implants in the treatment area.
- Active cancer or tumor in the treatment region.
- Pregnancy.
- Conditions such as stroke, Parkinson's disease, or rheumatoid arthritis that may confound results.
- Cognitive impairment, psychiatric illness, or other barriers to protocol adherence
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
The objective of the present study is to explore the effect of Transfer Energy Capacitive and Resistive Therapy (TECAR) therapy on pain, range of motion (ROM) and hand function in dupuytren's contracture patients (palmar fibromatosis).
Read the detailed description
Dupuytren contracture is a benign, progressive disease of the palmar fascia which results in shortening, thickening, and fibrosis of the fascia and aponeurosis of the palm driven by myofibroblastic proliferation.
TECAR therapy is considered a special form of energy that uses frequencies between 300 KHz and 1 MHz and is characterized as a non-invasive high-frequency energy that awakens the body's natural ability to self-regenerate.
The TECAR therapy can work in two modes of electric charge transfer: capacitive and resistive mode. The reactions produced by the capacitive system through the capacitive electrode are focused on tissues with higher electrolyte content, such as soft tissues and muscles, as opposed to the resistive system that focuses on larger and more resistant tissues such as tendons, bones and articulations. With these two modes of energy transfer, the therapy allows an increase in vasodilation, oxygenation, increase in microcirculation and increase in internal temperature. So, this study aimed to to explore the effect of Transfer Energy Capacitive and Resistive Therapy (TECAR) therapy on pain, range of motion (ROM) and hand function in dupuytren's contracture patients (palmar fibromatosis).
- Conditions
- Palmar Fibromatosis
- Being tested
- Transfer Energy Capacitive and Resistive (TECAR) therapy, Traditional therapy
- Medical subject headings
- Dupuytren Contracture
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transfer Energy Capacitive and Resistive (TECAR) therapyDevice
The apparatus used is comprised of a generator that supplies a signal at the frequency of 0.5 MHz and a maximum power of 300 watts (HCR900).The power can be regulated by controlling the quantity of transferred energy and the relative biological action. The counter electrode (Return Plate) that closes the circuit consists of a metal plate that is applied in opposition or a cylinder that is clasped.
The head of the device will be applied over the treated area for 20 minutes (min) (10 min of capacitive head and 10 min of resistive head), moderate to high intensity. It will be applied along and in circles over the affected palm, 3 sessions weekly for 6 weeks.
Traditional therapyOther
The patients will receive the traditional physical therapy program 3 sessions / week , for 6 weeks totally.
It consists of stretching exercise, flexor tendon glide and splinting.
| Study group | Role | What they receive |
|---|---|---|
| Transfer Energy Capacitive and Resistive (TECAR) therapy | Experimental | The patients will receive Tecar therapy, in addition to traditional therapy for 6 weeks Receives: Device: Transfer Energy Capacitive and Resistive (TECAR) therapy; Other: Traditional therapy |
| Traditional therapy group | Active comparator | The patients will receive traditional therapy only for 6 weeks . Receives: Other: Traditional therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Active range of motion (ROM) assessment of metacarpophalangeal joint (MCP):
- Patient Position: Sitting on a chair while his/her forearm will be in a mid position and supported with the involved hand on the plinth beside him/her.
- The therapist will stabilize the metacarpal bone.
- The goniometer axis will be placed over the dorsal surface of the MCP joint. The stationary arm of the goniometer will be placed parallel to the longitudinal axis of the metacarpal bone and the movable arm of the goniometer will be placed parallel to the longitudinal axis of the proximal phalanx.
- The patient will be asked to flex then extend his MCP joint to the limit of the motion (normally 0º-100º extension-flexion) then range of motion (ROM) will be documented.
Measured: 6 weeks
Active range of motion (ROM) assessment of proximal interphalangeal joint (PIP):
- Patient Position: Sitting on a chair while his/her forearm will be in a mid position and supported with the involved hand on the plinth beside him/her.
- The therapist will stabilize the proximal phalanx.
- The goniometer axis will be placed over the dorsal surface of the PIP joint. The stationary arm of the goniometer will be placed parallel to the longitudinal axis of the proximal phalanx and the movable arm of the goniometer will be placed parallel to the longitudinal axis of the middle phalanx.
- The patient will be asked to flex then extend his PIP joint to the limit of the motion (normally 0º-100º extension-flexion) then range of motion ROM will be documented.
Measured: 6 weeks
Pain intensity measurement
The Visual Analogue Scale (VAS) consists of a straight line with the endpoints defining extreme limits such as 'no pain at all' and 'pain as bad as it could be'.
The patient is asked to mark his pain level on the line between the two endpoints. The distance between 'no pain at all' and the mark then defines the subject's pain From 0 to 10 , (0 )means no pain and up to (10) means intolerable pain
Measured: 6 weeks
Secondary outcomes (1)
The Southampton Dupuytren's Scoring Scale
The Southampton Dupuytren's Scoring Scheme (SDSS) is a 5-item, 20-point patient-reported outcome measure (PROM) developed in 2014 to assess functional disability from Dupuytren's disease. It measures impairment across personal, domestic, work, and hobby activities, with scores from 0 (no problem) to 20 (worst), offering high sensitivity to change.
Measured: 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Mar 2026
- Study start2 Mar 2026 (estimated)
- Primary completion15 May 2026 (estimated)
- Study completion30 May 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Palmar FibromatosisStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 36 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Peter Milad Haroun, Cairo University
- Investigators
- Amir Zaki, PHD, Study director, Cairo UniversityHussein Mogahed, Professor, Study chair, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07443371
- Sponsor's protocol ID
- P.T.REC/012/006253
- Status last verified
- Feb 2026
- First submitted
- 25 Feb 2026
- Last updated
- 2 Mar 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Transfer Energy Capacitive and Resistive Therapy on Palmar Fibromatosis
- ClinicalTrials.gov ID
- NCT07443371
- Acronym / sponsor ID
- P.T.REC/012/006253
- Conditions
- Palmar Fibromatosis
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 36 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 2 Mar 2026 (estimated)
- Primary completion
- 15 May 2026 (estimated)
- Study completion
- 30 May 2026 (estimated)
- First posted
- 2 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of the present study is to explore the effect of Transfer Energy Capacitive and Resistive Therapy (TECAR) therapy on pain, range of motion (ROM) and hand function in dupuytren's contracture patients (palmar fibromatosis).
Detailed description
Dupuytren contracture is a benign, progressive disease of the palmar fascia which results in shortening, thickening, and fibrosis of the fascia and aponeurosis of the palm driven by myofibroblastic proliferation.
TECAR therapy is considered a special form of energy that uses frequencies between 300 KHz and 1 MHz and is characterized as a non-invasive high-frequency energy that awakens the body's natural ability to self-regenerate.
The TECAR therapy can work in two modes of electric charge transfer: capacitive and resistive mode. The reactions produced by the capacitive system through the capacitive electrode are focused on tissues with higher electrolyte content, such as soft tissues and muscles, as opposed to the resistive system that focuses on larger and more resistant tissues such as tendons, bones and articulations. With these two modes of energy transfer, the therapy allows an increase in vasodilation, oxygenation, increase in microcirculation and increase in internal temperature. So, this study aimed to to explore the effect of Transfer Energy Capacitive and Resistive Therapy (TECAR) therapy on pain, range of motion (ROM) and hand function in dupuytren's contracture patients (palmar fibromatosis).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Transfer Energy Capacitive and Resistive (TECAR) therapy | Experimental | Device: Transfer Energy Capacitive and Resistive (TECAR) therapy, Other: Traditional therapyThe patients will receive Tecar therapy, in addition to traditional therapy for 6 weeks |
| Traditional therapy group | Active comparator | Other: Traditional therapyThe patients will receive traditional therapy only for 6 weeks . |
Who may qualify
- Ages
- 40 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Ages of patients will be ranged from 40 to 70 years.
- Presence of palpable cords and/or digital contracture ≥ 20° at the metacarpophalengeal joint or Proximal interphalengeal joint joints .
- Clinical diagnosis confirmed by a hand surgeon or relevant specialist.
- All patients will enter the study having their informed consent
Key exclusion criteria (8 listed)
- Patient with severe contracture >30° or multiple digit involvement requiring surger.
- History of surgical release (fasciotomy, fasciectomy) or collagenase injection in the affected hand.
- Presence of infection, ulceration, or skin lesions on the treatment area.
- Presence of pacemakers, metal implants, or other electronic implants in the treatment area.
- Active cancer or tumor in the treatment region.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transfer Energy Capacitive and Resistive (TECAR) therapyThe apparatus used is comprised of a generator that supplies a signal at the frequency of 0.5 MHz and a maximum power of 300 watts (HCR900).The power can be regulated by controlling the quantity of transferred energy and the relative biological action. The counter electrode (Return Plate) that closes the circuit consists of a metal plate that is applied in opposition or a cylinder that is clasped. The head of the device will be applied over the treated area for 20 minutes (min) (10 min of capacitive head and 10 min of resistive head), moderate to high intensity. It will be applied along and in circles over the affected palm, 3 sessions weekly for 6 weeks. | Device | Transfer Energy Capacitive and Resistive (TECAR) therapy |
| Traditional therapyThe patients will receive the traditional physical therapy program 3 sessions / week , for 6 weeks totally. It consists of stretching exercise, flexor tendon glide and splinting. | Other | Traditional therapy group, Transfer Energy Capacitive and Resistive (TECAR) therapy |
Primary outcome
Active range of motion (ROM) assessment of metacarpophalangeal joint (MCP):
Time frame: 6 weeks
* Patient Position: Sitting on a chair while his/her forearm will be in a mid position and supported with the involved hand on the plinth beside him/her. * The therapist will stabilize the metacarpal bone. * The goniometer axis will be placed over the dorsal surface of the MCP joint. The stationary arm of the goniometer will be placed parallel to the longitudinal axis of the metacarpal bone and the movable arm of the goniometer will be placed parallel to the longitudinal axis of the proximal phalanx. * The patient will be asked to flex then extend his MCP joint to the limit of the motion (normally 0º-100º extension-flexion) then range of motion (ROM) will be documented.
Active range of motion (ROM) assessment of proximal interphalangeal joint (PIP):
Time frame: 6 weeks
* Patient Position: Sitting on a chair while his/her forearm will be in a mid position and supported with the involved hand on the plinth beside him/her. * The therapist will stabilize the proximal phalanx. * The goniometer axis will be placed over the dorsal surface of the PIP joint. The stationary arm of the goniometer will be placed parallel to the longitudinal axis of the proximal phalanx and the movable arm of the goniometer will be placed parallel to the longitudinal axis of the middle phalanx. * The patient will be asked to flex then extend his PIP joint to the limit of the motion (normally 0º-100º extension-flexion) then range of motion ROM will be documented.
Pain intensity measurement
Time frame: 6 weeks
The Visual Analogue Scale (VAS) consists of a straight line with the endpoints defining extreme limits such as 'no pain at all' and 'pain as bad as it could be'. The patient is asked to mark his pain level on the line between the two endpoints. The distance between 'no pain at all' and the mark then defines the subject's pain From 0 to 10 , (0 )means no pain and up to (10) means intolerable pain
1 secondary outcome
The Southampton Dupuytren's Scoring Scale
Time frame: 6 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Mar 2026.
Related trials for Palmar Fibromatosis
Not yet recruiting
Kinesitherapy Plus Osteopathy After Surgery for Dupuytren Disease
Dupuytren Disease
Not yet recruitingPhase 3
DEPART Study at Yale
Dupuytren's Contracture
Not yet recruiting
Understanding Patient Preferences When Deciding on a Voluntary Musculoskeletal Test
Non-traumatic Musculoskeletal Conditions, Carpal Tunnel Syndrome (CTS)
Recruiting
Radiation Therapy for Dupuytren's Contracture Following Non-Surgical Release
Dupuytren Contracture
Not yet recruitingPhase 2
NAC-REPAIR for Post-surgical Pain
Carpal Tunnel Surgery, Trigger Finger Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Amir Zaki, PHD study director
Cairo University
Hussein Mogahed, Professor study chair
Cairo University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Transfer Energy Capacitive and Resistive (TECAR) therapy and Traditional therapy in people with Palmar Fibromatosis, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Peter Haroun, Master (01289951508, DpTpeter2019@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Active range of motion (ROM) assessment of metacarpophalangeal joint (MCP): (time frame: 6 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Mar 2026.